Novartis Buys Avidity For $12B To Expand Rare Disease Pipeline

Novartis will buy Avidity Biosciences for $12B in cash, expanding into rare muscle disorders. The deal includes a 46% premium and a Spinco spinoff, strengthening Novartis’ U.S. presence amid Trump’s proposed pharma tariffs.